Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Egrifta
2. Tesamorelin
3. Th-9507
4. Th9507
1. 901758-09-6
2. Th9507
3. Unii-lgw5h38ve3
4. Tesamorelin Acetate [usan]
5. Lgw5h38ve3
6. (3e)-hex-3-enoylsomatoliberin (human) Acetate (salt)
1. Tesamorelin
2. Egrifta
Molecular Weight | 5196 g/mol |
---|---|
Molecular Formula | C223H370N72O69S |
Hydrogen Bond Donor Count | 84 |
Hydrogen Bond Acceptor Count | 78 |
Rotatable Bond Count | 187 |
Exact Mass | 5194.7444797 g/mol |
Monoisotopic Mass | 5192.7377700 g/mol |
Topological Polar Surface Area | 2400 Ų |
Heavy Atom Count | 365 |
Formal Charge | 0 |
Complexity | 12800 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 44 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Growth Substances
Signal molecules that are involved in the control of cell growth and differentiation. (See all compounds classified as Growth Substances.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 52416-107
Start Marketing Date : 2010-11-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73212-014
Start Marketing Date : 2020-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71052-520
Start Marketing Date : 2019-09-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76112-711
Start Marketing Date : 2014-07-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 82907-987
Start Marketing Date : 2024-08-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Details:
Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Egrifta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theratechnologies Receives Complete Response Letter from FDA for F8 Tesamorelin sBLA
Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Brand Name : Egrifta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2024
Details:
Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Egrifta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theratechnologies Receives FDA Update on Tesamorelin F8 Biologics License Application
Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Brand Name : Egrifta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 23, 2024
Details:
EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Egrifta MDV
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Details : EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Brand Name : Egrifta MDV
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 04, 2023
Details:
EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Dermatology Brand Name: Egrifta F8
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
Details : EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Brand Name : Egrifta F8
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 25, 2023
Details:
TH9507 (tesamorelin) stimulates growth hormone secretion (GHRH), and subsequently increases IGF-1 and IGFBP-3 levels. GHRH is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: EGRIFTA SV
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TH9507 (tesamorelin) stimulates growth hormone secretion (GHRH), and subsequently increases IGF-1 and IGFBP-3 levels. GHRH is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Brand Name : EGRIFTA SV
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 22, 2023
Details:
EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Dermatology Brand Name: Egrifta SV
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: World Orphan Drug Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : World Orphan Drug Alliance
Deal Size : Undisclosed
Deal Type : Agreement
Details : EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Brand Name : Egrifta SV
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 05, 2023
Details:
The priorities include the advancement of the clinical oncology pipeline, which is currently in a larger Phase 1b basket study, and the rapid growth of our existing marketed brands, EGRIFTA SV® and Trogarzo®.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Dermatology Brand Name: Egrifta SV
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Marathon Asset Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 13, 2022
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Marathon Asset Management
Deal Size : Undisclosed
Deal Type : Financing
Details : The priorities include the advancement of the clinical oncology pipeline, which is currently in a larger Phase 1b basket study, and the rapid growth of our existing marketed brands, EGRIFTA SV® and Trogarzo®.
Brand Name : Egrifta SV
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 13, 2022
Details:
The Phase 3 clinical trial will be a multicenter, double-blind, placebo-controlled two-part study to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Egrifta
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2021
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theratechnologies Provides Update on Its Planned Phase 3 Clinical Trial in NASH
Details : The Phase 3 clinical trial will be a multicenter, double-blind, placebo-controlled two-part study to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis.
Brand Name : Egrifta
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 15, 2021
Details:
Oral presentation includes data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Tesamorelin F8
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Oral presentation includes data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).
Brand Name : Tesamorelin F8
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 06, 2020
Details:
The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: F8
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.
Brand Name : F8
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2020
Regulatory Info :
Registration Country : USA
Brand Name : HUMALOG PEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100 UNITS/ML
Packaging :
Approval Date :
Application Number : 20563
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : HUMALOG KWIKPEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100 UNITS/ML
Packaging :
Approval Date :
Application Number : 20563
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : HUMALOG KWIKPEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 200UNITS/ML
Packaging :
Approval Date :
Application Number : 20563
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : HUMALOG TEMPO PEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100UNITS/ML
Packaging :
Approval Date :
Application Number : 20563
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
Brand Name : HUMALOG MIX 75/25 KWIKPEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 75 UNITS/ML;25 UNITS/ML
Packaging :
Approval Date :
Application Number : 21017
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
Brand Name : HUMALOG MIX 75/25 PEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 75 UNITS/ML;25 UNITS/ML
Packaging :
Approval Date :
Application Number : 21017
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
Brand Name : HUMALOG MIX 50/50
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 50 UNITS/ML;50 UNITS/ML
Packaging :
Approval Date :
Application Number : 21018
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
Brand Name : HUMALOG MIX 50/50 KWIKPEN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 50 UNITS/ML;50 UNITS/ML
Packaging :
Approval Date :
Application Number : 21018
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : HUMALOG KWIKPEN
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 200 UNITS/ML
Packaging :
Approval Date :
Application Number : 205747
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : EGRIFTA
Dosage Form : POWDER;SUBCUTANEOUS
Dosage Strength : EQ 1MG BASE/VIAL
Packaging :
Approval Date :
Application Number : 22505
Regulatory Info :
Registration Country : USA
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?